Halozyme Therapeutics Inc (HALO) stock news · P/E 36, rev $1.40B
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
This HALO news page leads with what Halozyme Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for HALO yet. We will not pad this page with generic market recap.
Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B and trailing P/E 35.7.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the HALO stock page; for the tape open the quote page.
HALO stock news FAQ
What are HALO's latest revenue and net income?
Latest cached Halozyme Therapeutics Inc (HALO) revenue for Dec 31, 2025 was $1.40B. Net income was $316.9M. Statements: https://lician.com/financials/halo
How did HALO revenue change from the prior cached period?
Cached Halozyme Therapeutics Inc (HALO) revenue was up 37.6% from $1.02B (Dec 31, 2024) to $1.40B (Dec 31, 2025). Statements: https://lician.com/financials/halo
What is HALO's P/E ratio?
Halozyme Therapeutics Inc (HALO) trailing P/E is 35.7 on the latest cached fundamentals snapshot.
What is HALO's market cap?
Halozyme Therapeutics Inc (HALO) market cap is $7.10B on the latest cached fundamentals snapshot.
What kind of company is HALO?
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Where is HALO stock news listed?
Cached stock news for Halozyme Therapeutics Inc (HALO) is listed at https://lician.com/news/halo. Filings: https://lician.com/sec/halo
Not investment advice.